Industry Trend

Site Sections


Menu













© 2023. All Rights reserved.

Overview for MERCK & CO.

All Data per May 26, 2023

Industry:

Drug Manufacturers—General

Last Close:

111.07 USD

Expected Dividend:

2.67 %

Payoffs per Year:

4
Business Summary

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.


Competitors View

Ordering

PFIZER

USA
0.89 3.74%
4.36%
6.07% 4.49% 1.0 0.61
-43.29%
46.05 16.02% 48.64 1.0

ABBVIE

USA
1.02 3.5%
4.3%
10.17% 5.07% 1.0 3.15
-14.88%
42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR
1.06 3.6%
2.11%
5.97% 4.3% 0.5 16.21
-3.86%
67.14 17.71% 38.41 3.0

SANOFI

FRA
1.11 3.8%
3.58%
1.59% 3.73% 1.0 0.88
-12.18%
49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN
0.98 1.38%
2.08%
16.13% 2.65% 1.0 3.06
-38.8%
42.96 15.38% 77.21 5.0

MERCK & CO.

USA
1.09 3.4%
2.67%
5.29% 3.94% 1.0 3.67
-11.68%
47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA
0.95 2.6%
4.47%
2.48% 2.66% 1.0 0.53
-24.44%
34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN
1.01 2.35%
2.85%
19.78% 5.38% 1.0 1.47
-19.06%
31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA
1.1 2.36%
1.06%
14.8% 4.25% 1.0 11.83
-12.71%
45.05 7.83% 21.77 9.0

AMGEN

USA
0.95 2.75%
3.93%
10.11% 3.97% 1.0 1.83
-17.4%
38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN
1.07 2.05%
0.7%
6.06% 2.46% 1.0 10.21
-17.26%
41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN
0.95 1.65%
1.91%
8.0% 2.16% 1.0 3.07
-15.61%
44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN
1.01 2.16%
1.93%
0.0% 1.98% 1.0 0.44
-14.62%
29.23 12.66% 72.92 13.0

ROCHE

CHE
0.92 3.1%
3.27%
1.69% 3.06% 1.0 0.55
-23.37%
40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA
1.04 3.5%
3.89%
3.61% 3.76% 0.5 0.24
-42.43%
36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA
0.96 2.69%
3.05%
5.9% 3.2% 1.0 0.19
-12.62%
46.37 -0.95% 40.99 16.0

BAYER

GER
1.06 2.96%
3.68%
0.81% 2.81% 0.5 -0.3
-58.76%
37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR
1.02 6.49%
2.62%
0.0% 5.95% -1.0 0.02
-24.56%
47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP
0.91 1.1%
0.0%
-53.18% 0.2% -0.5 -0.11
-65.73%
32.66 2.01% 38.04 19.0


Information for MERCK & CO.

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 2.96 111.07 2.67
2022 2.80 110.95 2.52
2021 2.64 76.64 3.44
2020 2.48 78.05 3.18
2019 2.26 86.78 2.60
2018 1.99 71.92 2.77
2017 1.89 53.69 3.52
2016 1.85 56.17 3.29
2015 1.81 50.40 3.59
2014 1.77 54.19 3.27
2013 1.73 47.76 3.62

Fundamentals

Chart